Clinical Trials Directory

Trials / Terminated

TerminatedNCT01238588

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Brigham and Women's Hospital · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will be associated with less inflammation including less atherosclerotic plaque inflammation (inflammation of the vessel walls).

Conditions

Interventions

TypeNameDescription
DRUGSevelamer Carbonate (Renvela)Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.

Timeline

Start date
2011-06-10
Primary completion
2016-04-08
Completion
2016-04-08
First posted
2010-11-10
Last updated
2017-07-31
Results posted
2017-06-21

Locations

10 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01238588. Inclusion in this directory is not an endorsement.

The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan (NCT01238588) · Clinical Trials Directory